- www.karustherapeutics.com
- 1
Over recent years, Karus Therapeutics has invested in the research and development of (i) KA2237, an oral, PI3K-p110β/δ-selective inhibitor and (ii) KA2507, an oral, selective HDAC6 inhibitor and (iii) a research program focussing on orally..
Relevance: 75.63074